These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 25569709)

  • 1. Transformation of oligomers of lipidated peptide induced by change in pH.
    Wang Y; Lomakin A; Kanai S; Alex R; Benedek GB
    Mol Pharm; 2015 Feb; 12(2):411-9. PubMed ID: 25569709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peptide Oligomerization Memory Effects and Their Impact on the Physical Stability of the GLP-1 Agonist Liraglutide.
    Bothe JR; Andrews A; Smith KJ; Joyce LA; Krishnamachari Y; Kashi S
    Mol Pharm; 2019 May; 16(5):2153-2161. PubMed ID: 30990695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The molecular basis for the prolonged blood circulation of lipidated incretin peptides: Peptide oligomerization or binding to serum albumin?
    Wang Y; Lomakin A; Kanai S; Alex R; Belli S; Donzelli M; Benedek GB
    J Control Release; 2016 Nov; 241():25-33. PubMed ID: 27578099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pH-Induced Switch in Human Glucagon-like Peptide-1 Aggregation Kinetics.
    Zapadka KL; Becher FJ; Uddin S; Varley PG; Bishop S; Gomes Dos Santos AL; Jackson SE
    J Am Chem Soc; 2016 Dec; 138(50):16259-16265. PubMed ID: 27998088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oligomerization of a Glucagon-like Peptide 1 Analog: Bridging Experiment and Simulations.
    Frederiksen TM; Sønderby P; Ryberg LA; Harris P; Bukrinski JT; Scharff-Poulsen AM; Elf-Lind MN; Peters GH
    Biophys J; 2015 Sep; 109(6):1202-13. PubMed ID: 26340816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice.
    Kissow H; Hartmann B; Holst JJ; Viby NE; Hansen LS; Rosenkilde MM; Hare KJ; Poulsen SS
    Regul Pept; 2012 Nov; 179(1-3):91-100. PubMed ID: 22989472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oligomerization, albumin binding and catabolism of therapeutic peptides in the subcutaneous compartment: An investigation on lipidated GLP-1 analogs.
    Gallo M; Vanni D; Esposito S; Alaimo N; Orvieto F; Rulli F; Missineo A; Caretti F; Bonelli F; Veneziano M; Orsatti L; Monteagudo E
    J Pharm Biomed Anal; 2022 Feb; 210():114566. PubMed ID: 35042144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liraglutide: once-daily GLP-1 agonist for the treatment of type 2 diabetes.
    Ryan GJ; Hardy Y
    J Clin Pharm Ther; 2011 Jun; 36(3):260-74. PubMed ID: 21545609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Conserved Hydrophobic Moiety and Helix-Helix Interactions Drive the Self-Assembly of the Incretin Analog Exendin-4.
    Wolff M; Gast K; Evers A; Kurz M; Pfeiffer-Marek S; Schüler A; Seckler R; Thalhammer A
    Biomolecules; 2021 Sep; 11(9):. PubMed ID: 34572518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Harnessing the incretin system beyond glucose control: potential cardiovascular benefits of GLP-1 receptor agonists in type 2 diabetes.
    Cariou B
    Diabetes Metab; 2012 Oct; 38(4):298-308. PubMed ID: 22672960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
    Deacon CF; Mannucci E; Ahrén B
    Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of glucagon-like peptide-1 on the beta cell.
    Vilsbøll T
    Diabetes Obes Metab; 2009 Dec; 11 Suppl 3():11-8. PubMed ID: 19878257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus.
    Montanya E; Sesti G
    Clin Ther; 2009 Nov; 31(11):2472-88. PubMed ID: 20109994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular effects of glucagonlike peptide-1 agonists.
    Davidson MH
    Am J Cardiol; 2011 Aug; 108(3 Suppl):33B-41B. PubMed ID: 21802579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differentiating incretin therapies based on structure, activity, and metabolism: focus on liraglutide.
    Grossman S
    Pharmacotherapy; 2009 Dec; 29(12 Pt 2):25S-32S. PubMed ID: 19947814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical efficacy of GLP-1 agonists and their place in the diabetes treatment algorithm.
    Unger J
    J Am Osteopath Assoc; 2011 Feb; 111(2 Suppl 1):eS2-9. PubMed ID: 21389296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with Type 2 diabetes and obesity.
    Gault VA; Kerr BD; Harriott P; Flatt PR
    Clin Sci (Lond); 2011 Aug; 121(3):107-17. PubMed ID: 21332446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blendable peptide-polymer nanofibers to modulate mechanical properties of polymers.
    Hentschel J; Börner HG
    Macromol Biosci; 2009 Feb; 9(2):187-94. PubMed ID: 19127601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Self-assembly and polymerization of diacetylene-containing peptide amphiphiles in aqueous solution.
    van den Heuvel M; Löwik DW; van Hest JC
    Biomacromolecules; 2008 Oct; 9(10):2727-34. PubMed ID: 18785773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
    Jellinger PS
    Postgrad Med; 2011 Jan; 123(1):53-65. PubMed ID: 21293084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.